September 11, 2007 —The BC-SeraPro blood serum test for detection of breast cancer is being developed by Power3, in conjunction with Mercy Hospital Women's Center.
The test analyzes biomarkers, or specific proteins, that indicate the difference between normal breast tissue, a benign breast disease, and a breast cancer. A recent study showed that the BC-SeraPro diagnostic test detected the disease accurately in 80 to 90 percent of the patients.
Proteomics, the state-of-the-art technology that Power3 applies, involves identifying protein biomarkers that differ from the body's normal protein markers. These particular markers can be used to both detect diseases early and as targets for new drug treatments. Using proteomics, distinctive proteins can be mapped to create a profile of a disease that is distinctive for that particular disease. Power3 has identified 22 biomarkers that are utilized in the detection of early breast cancer.
In addition to its usefulness in offering early diagnosis, BC-SeraPro can potentially monitor the progression of the disease to determine if a specific therapy is effective.
For more information: www.power3medical.com